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Introduction
Diabetic autonomic neuropathy is one of the least recog-
nised and understood complications of diabetes despite
its significant negative impact on survival and quality of
life in people with diabetes (Vinik et al., 2003). Diabetes
may affect any part of the autonomic nervous system
harming sweat glands, the gastrointestinal tract system,
the adrenal medullary system, and last but not least the
cardiovascular and the genitourinary system. The crucial
point about diabetic autonomic neuropathy is that sub-
clinically it can occur as early as within a year of diagno-
sis in patients with type 2 diabetes (Pfeifer et al., 1984).
Therefore, mortality and morbidity may be increased at a
very early stage in patients with diabetes. In fact the
5-year mortality rate is five times higher for individuals
with cardiovascular autonomic neuropathy (CAN) than
for individuals without cardiovascular autonomic involve-
ment (Ziegler, 1999).
Erectile dysfunction (ED) is a common complication of
diabetes; the reported prevalence ranges from 27% to
75% (Bacon et al., 2002). ED is defined as the consistent
inability to attain and maintain an erection adequate for
sexual intercourse, usually qualified by being present for
several months and occurring at least half the time. There
are multiple causes for ED in patients with diabetes.
These include vascular, endocrine, neurological and psy-
chogenic aetiologies. Autonomic neuropathy is one of the
main causes for ED (Ziegler, 2001).
Quadri et al. (1989) studied diabetic patients with sex-
ual dysfunction concluding that there is a significant asso-
ciation between ED and cardiovascular parasympathetic
impairment. In a highly selected group of patients with
no clinically significant cardiovascular disease, is ED still
always associated with CAN? It has been proved that vas-
cular ED could help in detection of heart disease before
development of symptoms (Gazzaruso et al., 2004), but
can ED secondary to autonomic failure predict future
development of CAN?
In our study, we assessed this hypothesis in a specific
group of males with type 2 diabetes with highly selected
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Summary
The study investigated whether there is a significant association between erec-
tile dysfunction (ED) secondary to autonomic failure, and cardiovascular auto-
nomic neuropathy (CAN) in male patients suffering from type 2 diabetes.
Twenty-two patients suffering from type 2 diabetes were recruited for this
study after satisfying the stringent exclusion criteria used in the first stage. They
had no evidence of overt cardiovascular disease, hypertension, neurological,
renal or thyroid disease. Each subject was assessed for ED and CAN using stan-
dardized tests. Six patients were suffering from CAN while 10 patients were
suffering from ED. There was no significant association between CAN and
autonomic ED (P = 1). Three patients with normal erectile function had CAN,
whilst three patients with ED had CAN. Further analysis demonstrates a signifi-
cant increase in association between ED and CAN with age (P = 0.036). These
results show that ED secondary to autonomic neuropathy is not significantly
associated with CAN in this specific group of patients. Nonetheless, the study
reveals that ED is a sentinel symptom for future development of CAN.
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ischaemic heart disease, hypertension, renal, neurological
or thyroid disease.
Patients and methods
In our study, males with type 2 diabetes were recruited
from Diabetes Clinic, St Lukes Hospital, Malta. In the
first stage, each consecutive patient attending the clinic
on each successive Wednesday, who had never com-
plained of any significant shortness of breath on exertion
or at rest, paroxysmal nocturnal dyspnoea, orthopnoea or
lower limb swelling, chest pain, loss of consciousness or
palpitations were chosen to enter the study. Any of the
patients chosen, who had any of the following criteria
was excluded:
1. Those on drugs known to affect autonomic nervous
system, e.g. anti hypertensives, phenothiazines, tricyclic
anti-depressants, benzodiazepines.
2. Those with overt renal failure, thyroid disease and
those with a history or clinical evidence of cardiovascular
or neurological disease or any other systematic disease.
3. Patients with a history of hypertension.
4. Those with any disease or condition causing polyneu-
ropathy.
Those who fulfilled these criteria had their blood pres-
sure checked after 5 min of rest on at least two occasions.
The mean was taken. Those with a blood pressure of
>130/80 were excluded from the study. The blood pres-
sure was rechecked at each different stage of the study.
Initially, 38 patients were recruited over 4 months.
On entry into the study patients were identified by an
entry number. The data collected for every patient
included their age, year of diagnosis of diabetes, anti-
diabetic treatment and history of smoking. Their glycosy-
lated haemoglobin (Hba1C) level was also measured.
Informed consent was obtained from all subjects. This
study was approved by the ethics committee of the Uni-
versity of Malta.
A maximal ECG exercise stress test using the standard
Bruce protocol was carried out on all 38 patients, with a
threadmill using a 12-lead ECG (Marquette CASE 8000
exercise testing system). Each patient as a minimum
needed to attain 90% age-predicted maximum heart rate
for the test to be valid. Standard features for positivity
were used, namely: ischaemic chest pain consistent with
angina during exercise, a 10 mmHg or more drop in sys-
tolic BP during exercise when compared to baseline, exer-
cise induced arrhythmias and planar or downsloping ST
depression of 1 mV or more at 80 ms from J-point.
Those patients who had a positive stress test were
excluded from the study and were referred for a coronary
angiogram. Those with an abnormal resting ECG or any-
one developing significant shortness of breath or intermit-
tent claudication were also excluded. Ten patients in total
were eliminated.
To exclude other potential causes for ED besides auto-
nomic neuropathy, each of the other 28 patients had a
Hospital Anxiety and Depression Scale test to exclude
psychological disease (Zigmond & Snaith, 1983), had
their peripheral lower limb pulses examined, were
assessed for loss of perianal sensation and their blood tes-
tosterone and prolactin levels measured. Any abnormali-
ties in these tests excluded the patient from the study.
Those drinking more than three units of alcohol every
day or those with a history of prostate problems or pelvic
pathology were also excluded. Four patients were
excluded.
During the period of the first stage of the study, further
two patients were excluded after being started on ACE
inhibitors by their GP for development of hypertension.
Thereafter 22 patients were assessed for CAN and ED in
the second stage of the study.
Erectile dysfunction assessment
Each patient who entered the second stage was assessed
for ED. The assessment was made by using the Interna-
tional Index of Erectile Function-5 (IIEF-5) as a diagnos-
tic tool (Rosen et al., 1999). The questions asked were the
following: Over the past 6 months: (i) How do you rate
your confidence that you could get and keep an erection?
(ii) When you had an erection with sexual stimulation,
how often were your erections hard enough for penetra-
tion? (iii) During sexual intercourse, how often were you
able to maintain your erection after you had penetrated
your partner? (iv) During sexual intercourse, how difficult
was it to maintain your erection to completion of inter-
course? and (v) When you attempted sexual intercourse,
how often was it satisfactory for you? The IIEF-5 score
represents the sum of these questions with a maximum
score of 25; patients with a score of 21 or less were taken
to be suffering from ED. The questionnaires were analy-
sed in a blinded fashion independently of the results of
CAN testing.
Cardiovascular autonomic neuropathy assessment
Each patient then underwent tests for CAN. The three
tests of cardiovascular autonomic nerve function were: (i)
the Expiration : Inspiration (E : I) ratio (obtained from
R-R variations); (ii) the Valsalva ratio; and (iii) the stand-
ing 30 : 15 ratio. These tests use deep breathing, the
Valsalva manoeuvre, and standing from a supine position,
respectively, as provocative stimuli. Autonomic tests were
applied under standardized conditions between 09:00 and
12:00 am, at least 2 h after following a light breakfast.
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The patients were not allowed to drink coffee or tea or
smoke on the day of the testing. Diagnosis of CAN was
based on an abnormality in one of the tests assessing
heart rate variability (HRV); this was confirmed on
repeating the test a week after. It has been stated that an
abnormality in one of the above tests of HRV is indica-
tive of early autonomic neuropathy (Vinik et al., 2003).
E : I ratio
The subject remained supine and took breaths deeply at
the rate of one breath per 10 s (i.e. six breaths per min-
ute) for 1 min while being monitored by ECG. The E : I
is the ratio of the mean of the longest R-R intervals dur-
ing deep expirations to the mean of the shortest R-R
intervals during deep inspirations. This is an indication of
parasympathetic function. The following age-related val-
ues were used to define abnormal/normal levels: lowest
normal value of E/I ratio: age 20–24 : 1.17; 25–29 : 1.15;
30–34 : 1.13; 35–30 : 1.12; 40–44 : 1.10; 45–49 : 1.08;
50–54 : 1.07; 55–59 : 1.06; 60–64 : 1.04; 65–69 : 1.03;
70–75 : 1.02 (Vinik, 2002; Vinik & Mehrabyan, 2003).
Valsalva manoeuvre
In the standard Valsalva manoeuvre, the supine patient
was connected to an ECG monitor, and forcibly exhaled
for 15 s against a fixed resistance with an open glottis.
The patient maintained constant pressure at 40 ml over
the 15-s interval. The Valsalva ratio is the longest R-R
occurring within 45 s of peak heart rate divided by the
shortest R-R and is indicative of overall condition of the
parasympathetic and sympathetic fibres (mainly parasym-
pathetic). Ratios £1.20 were taken as abnormal while
those ‡1.21 were normal (Ewing et al., 1973).
Heart rate response to standing
The patient was connected to the heart rate monitor
while in the supine position. The patient then stood up
to a full upright position, and the ECG was monitored
for an additional period while standing. The heart rate
tracing was used to calculate the ratio of the longest R-R
interval (about beat 30) after the stand to the shortest
R-R interval (about beat 15). This measure, called the
30 : 15 ratio, reflects the overall condition of the para-
sympathetic fibres. Ratios £1.030 were taken as abnormal
while those ‡1.031 were normal (Campbell et al., 1978).
Statistical methods
Frequencies of impotence and CAN in the sample are
established. The results of the cardiovascular tests are
expressed as mean and 95% confidence intervals (CI) for
this small sample. As the sample size was small, statistical
analysis was carried out using nonparametric tests such as
the Fisher’s exact test and the Mann–Whitney test. Logistic
regression analysis was used to assess for confounding fac-
tors. A result was considered significant when P was <0.05.
Results
The mean age of the patients reaching the second stage
was 54.62 (95% CI 50.63–58.6 years) and the mean rest-
ing heart rate was 83 bpm (95% CI 77–88). Age and
heart rate are two potential confounding factors when
assessing CAN. The patient characteristics for the two
main groups and P-values for the differences between
groups are tabulated (Table 1).
From this sample of 22 patients, 10 patients were
found to have ED, that is attained a score of 21 or less
on IIEF-5, whilst six patients were suffering from auto-
nomic neuropathy, using criteria specified above.
From the 12 patients with no ED, three patients were
suffering from CAN, whilst from the 10 patients with ED,
three patients had CAN. There was no significant associa-
tion (P = 1.00) between autonomic ED and CAN in this
cohort. This analysis was performed using the Fisher’s
exact test. Figure 1 shows the graphical representation of
these findings.
When assessing E : I ratios, one of 10 patients (10%)
with ED had an impaired response whilst one of 12
patients (8.3%) without ED had evidence of CAN. The
mean value for the E : I ratios (difference of measured
E : I ratios from normal target values for each patient’s
age) in the ED group was 0.147 (95% CI 0.055–0.24)
whilst that in the non-ED group was 0.141 (95% CI
0.034–0.21). This difference was not significant (P = 0.64)
(Fig. 2).








(bpm) (P = 0.791)
Erectile dysfunction 59.7 (54.5–64.7) 10.1 (4.1–16.0) 7.4 (5.6–9.3) 83.4 (74.8–92.1)
No erectile dysfunction 50.8 (44.6–56.9) 6.0 (4.2–7.7) 7.1 (5.7–8.5) 82.3 (71.3–93.3)
Hba1c, glycosylated haemoglobin.
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When assessing Valsava ratios two of 10 patients (20%)
with ED had an abnormal response whilst three of 12
patients (25%) not suffering from ED had impaired
ratios. The mean value for Valsava ratios was 1.44 (95%
CI 1.27–1.61) in the ED group with mean value for the
non-ED group being 1.45 (95% CI 1.29–1.55). The differ-
ence was again not significant (P = 0.84) (Fig. 3).
None of the patients in the sample had an abnormal
30 : 15 ratio test. The mean value for the ED group was
1.162 (95% CI 1.08–1.24) and for the non-ED group was
1.168 (95% CI 1.05–1.27) with a nonsignificant difference
between the groups (P = 0.947) (Fig. 4).
Through logistic regression analysis, for each 1% rise in
Hba1c there was no significant increase in association
between ED and CAN (P = 0.866). There was also no sig-
nificant increase in association between CAN and ED
when adjusting for the time from diagnosis (P = 0.097)
Fig. 1 Presence of erectile dysfunction and cardiovascular autonomic
neuropathy in study group.
Fig. 2 Calculated difference in expiratory : inspiratory ratios from
normal target values in patients with or without erectile dysfunction
(ED).
Fig. 3 Valsava ratio measurements in patients with or without erec-
tile dysfunction (ED).
Fig. 4 30:15 ratio test in patients with or without erectile dysfunction
(ED).
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although in this case a larger sample might have resulted
in a significant end result. On the other hand, age was
found to have a significant effect; the association between
CAN and ED significantly increased (P = 0.036) with age.
In the study, five of 12 patients (41.7%) with no ED were
ex-smokers whilst three of 10 patients (30%) with ED
smoked. Using the Mantel–Haenszel Common odds ratio
estimation, smoking did not significantly effect the associ-
ation between CAN and ED (P = 0.907).
Discussion
Reduced HRV is the earliest indicator of CAN. CAN has
a prevalence of between 17% and 22% in patients with
type 1 and type 2 diabetes (Neil et al., 1989). The impor-
tance of CAN with respect to morbidity and mortality for
patients with diabetes has led to various guidelines being
developed for assessment of autonomic dysfunction.
According to the American Academy of Neurology (1996)
the tests used in our study are established, and are
accepted as appropriate by medical practitioners, when
used for testing for CAN. Vinik et al. (2003) state that an
abnormal result in one test for HRV is indicative of auto-
nomic neuropathy.
In our study, when using these criteria, we found that
there was no significant association between the presence
of autonomic ED and CAN in a well characterised group
(P = 1). Each different test for CAN did not show a sig-
nificant association. The strength of our study lies in the
fact that our patients were likely to be suffering from ED
secondary to diabetic autonomic neuropathy and not to
any other cause. Great care was taken to exclude patients
with hypertension or overt cardiovascular disease, endo-
crine, and other neurological or psychological illnesses, all
of which would be confounding variables for a cause for
ED. Besides this, our patients did not abuse alcohol and
had no history of prostate disease or other pelvic pathol-
ogy. To our knowledge, no other study has evaluated this
association in this way. Quadri et al. (1989) revealed an
association between E : I HRV tests and impotence, how-
ever, they did not characterize ED similarly.
Our study reveals that ED is not a reliable diagnostic
marker of CAN, but it brings up another important
point. Ewing et al. (1980) had revealed that in a group of
patients with diabetes suffering from impotence alone,
these developed abnormal tests for CAN in the follow-up
period. In our analysis, we notice that with age the associ-
ation between CAN and ED significantly increases
(P = 0.036). Besides this, there could possibly be an asso-
ciation between the years from diagnosis of diabetes and
the development of CAN in patients with ED
(P = 0.097). If a larger sample was studied, this might
have been significant. Therefore, these findings should
alert us that ED may be an early clinical indicator of
forthcoming autonomic damage.
One of the main limiting factors for the study is that the
sample size is small. One must understand that patients
with diabetes with these special characteristics are not easy
to recruit and a substantial amount of patients were lost in
the stringent exclusion criteria used. The very high non-
significant P-value of 1.00 when assessing the association
between CAN and ED indicates that increasing the sample
size might not change the result. This makes our results
valid. Age was significantly different between groups. This
observation was expected as the incidence of ED has been
shown to be strongly associated with age (Keles et al.,
2005). The only way to eliminate this confounding factor
would be to select an age-matched group, but this would
restrict further an already limited sample population. As
there was no significant association between ED and CAN
in this cohort, this finding has no influence on the out-
come of the study. Another limitation is that to exclude a
vascular cause for ED we did not directly measure the
penile blood pressures. Chiurlia et al. (2005) revealed that
coronary atherosclerosis is more severe in patients with
vascular ED. Keeping these findings in mind, to eliminate
patients with a possibility of vascular ED, we excluded
patients with a high probability of cardiovascular disease,
that is those with history of coronary artery disease,
exertional chest pain, positive elective stress tests, hyperten-
sion, intermittent claudication and nonpalpable lower limb
pulses. Caused by these limitations our investigation
should be primarily considered as a pilot study.
To conclude, this study, although small, demonstrates
that ED in patients with type 2 diabetes, with no associ-
ated comorbidities, is not diagnostic of CAN. Most
importantly, this study reveals that the presence of ED
might be a portent of future CAN. We therefore insist
that at least simple bedside tests for autonomic neuropa-
thy should be performed routinely on patients with dia-
betes suffering from ED. This will help establish the
diagnosis of CAN as early as possible and thus prevent
associated mortality and morbidity. The results of this
study support the need for further research, through lar-
ger experimental designs, in this area.
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